IRulya Therapeutics Inc. Common Stock
IRLA
50 hedge funds and large institutions have $594M invested in IRulya Therapeutics Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 5 reducing their positions, and 3 closing their positions.
420% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 5
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
310% more capital invested
Capital invested by funds: $145M → $594M (+$449M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
28% more funds holding
Funds holding: 39 → 50 (+11)
17.65% more ownership
Funds ownership: 21.79% → 39.43% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$9.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.38M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.78M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$3.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alphabet Inc
Mountain View,
California
|
-$3.71M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.25M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$591K |
| 4 |
Millennium Management
New York
|
-$529K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$157K |
IRLA Hedge Fund Activity: Q4 2019 in Review
50 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q4 2019, worth a combined $594M — up 310% from $145M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IRLA positions and 3 closed out — a net gain of 11 holders — while 26 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $13M. The largest seller was Alphabet Inc, cutting an estimated $3.71M.
- 50 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q4 2019, up from 39 in Q3 2019.
- Funds reported $594M of IRulya Therapeutics Inc. Common Stock stock for Q4 2019, up 310% quarter-over-quarter.
- 14 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q4 2019 and 3 closed out, a net change of +11 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $13M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q4 2019 was Alphabet Inc, an estimated $3.71M sold.
Based on aggregated 13F filings for Q4 2019.